X0306 4 2013-09-16 0 0001070698 Raptor Pharmaceutical Corp RPTP 0001235470 STARR CHRISTOPHER M C/O RAPTOR PHARMACEUTICAL CORP. 5 HAMILTON LANDING, SUITE 160 NOVATO CA 94949 1 1 0 0 Chief Executive Officer Common Stock 2013-09-16 4 M 0 5000 2.97 A 704370 D Common Stock 2013-09-16 4 M 0 15000 2.83 A 719370 D Common Stock 2013-09-16 4 M 0 5000 3.54 A 724370 D Common Stock 2013-09-16 4 S 0 25000 14.2072 D 699370 D Stock options (right to buy) 2.97 2013-09-16 4 M 0 5000 0 D 2011-03-01 2020-10-11 Common Stock 5000 167524 D Stock options (right to buy) 2.83 2013-09-16 4 M 0 15000 0 D 2006-11-26 2016-05-25 Common Stock 15000 14140 D Stock options (right to buy) 3.54 2013-09-16 4 M 0 5000 0 D 2010-11-22 2020-11-21 Common Stock 5000 340054 D Stock options (right to buy) 2.02 2010-03-09 2020-03-08 Common Stock 46750 35548 D Stock options (right to buy) 5.13 2012-03-22 2021-09-21 Common Stock 460064 460064 D Stock options (right to buy) 5.49 2013-03-25 2022-09-24 Common Stock 150000 150000 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 13, 2013. This transaction was executed in multiple trades at prices ranging from $13.98 to $14.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Stock options vest 6/48ths on the six month anniversary of grant date and 1/48th per month thereafter. Fully vested and exercisable. Options vest 6/36ths on the six month anniversary of grant date and 1/36th per month thereafter. Stock options vest starting on September 1, 2010, 6/48ths on March 1, 2011 and 1/48th per month thereafter. Stock option vests 25% immediately and 75% pro rata over 36 months. Options vest 6/48ths immediately and 1/48th per month thereafter. The shares listed as owned in column 9 represent the total shares for each respective option. Previous reports reflected aggregate amounts of option shares in column 9. The holding lines included on this Form 4 are included solely to correct the breakdown of shares among various stock options and are not meant to reflect any change in beneficial ownership of option shares other than those reported as a transaction on this Form 4. /s/ Kim R. Tsuchimoto, Raptor Pharmaceutical Corp., Attorney-in-fact 2013-09-18